Counterfactual Thinking and Decision-making in Parkinson's Disease (CT_PD)
Counterfactual Thinking About Clinical Decision and Decision-making in the Context of the Parkinson's Disease.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Luca G Grappiolo
- Phone Number: 2894 +390261911
- Email: luca.grappiolo@auxologico.it
Study Contact Backup
- Name: Federica Scarpina, PhD
- Phone Number: 4003 +39032351
- Email: f.scarpina@auxologico.it
Study Locations
-
-
VCO
-
Piancavallo, VCO, Italy, 28824
- IRCCS Istituto Auxologico Italiano - Ospedale San Giuseppe
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
• Diagnosis of Parkinson's disease, according to the medical assessment performed by trained neurologists.
Exclusion Criteria:
- Diagnosis of Obstructive Sleep Apnea Syndrome, according to the clinical assessment;
- Concurrent neurological, neurodevelopmental (e.g., autism), motor, and/or psychiatric disorders;
- Dementia, according to the clinical/neuropsychological assessment.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cases
Individuals diagnosed with Parkinson's Disease consecutively recruited at the beginning of rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy).
Concurrent neurological, neurodevelopmental (e.g., autism), motor or psychiatric disorders were exclusion criteria.
|
All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences.
Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire).
Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
|
|
Controls
Age-matched healthy individuals recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
|
All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences.
Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire).
Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CIT score
Time Frame: Baseline
|
Score at the Counterfactual inference test (CIT).
The questionnaire is a four question forced choice test based on past research regarding factors that enhance counterfactual thinking.
For each of the four questions, events experienced by two individuals are presented, and three response options are given.
Only one option is the valid: the score is 1.
For the not valid options, the score will be 0. Overall, the score range for the questionnaire is from 0 (worse performance) to 4 (best performance).
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Decision-making index
Time Frame: Baseline
|
Score at the Decision-Making Questionnaire.
The self-report questionnaire assesses the decision making ability according to 7 questions, with a 5-item Likert's scale.
The overall score (i.e., the sum of the scores at all questions) can range from 7 (worse decision making strategy) to 35 (best decision making strategy).
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sofia Tagini, PhD, IRCCS Istituto Auxologico Italiano
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 21C129
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.